Chronic obstructive pulmonary disease (COPD) has been recently defined as an independent risk factor for pulmonary embolism and patients with COPD are frequently prescribed β2AR agonists as a bronchodilator. Here, ADRB2 is linked to chronic obstructive pulmonary disease.